AbCellera Biologics Inc.
ABCL Healthcare Biotechnology
AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024. In the quarter to June 2026, revenue fell 76.3%, EPS fell 50.0% and free cash flow grew 152.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ABCL
AbCellera Biologics Inc. (ABCL) P/E ratio
AbCellera Biologics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 5,890× (December 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 16.9× | (34.82%) |
| FY2021 | 26.0× | (51.73%) |
| FY2020 | 53.9× | (99.09%) |
| FY2019 | 5,890× | 0.00% |
| FY2018 | 5,890× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 22 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | n/m |
| LEGN Legend Biotech Corporation Sponsored ADR compare | n/m |
| DFTX Definium Therapeutics, Inc. compare | n/m |
| TNGX Tango Therapeutics, Inc. compare | n/m |
| DNTH Dianthus Therapeutics, Inc. compare | n/m |
| ABCL AbCellera Biologics Inc. | n/m |
| RLAY Relay Therapeutics, Inc. compare | n/m |
| ARQT Arcutis Biotherapeutics, Inc. compare | 131× |
| TLX Telix Pharmaceuticals Limited compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)